Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News Analysis
Nature Reviews Drug Discovery 3, 295–296 (1 April 2004) | doi:10.1038/nrd1362
Tadalafil and vardenafil
&
Abstract
In 2003, two inhibitors of phosphodiesterase 5 (PDE5) — tadalafil (Cialis; Lilly ICOS) and vardenafil hydrochloride (Levitra; Bayer/ GlaxoSmithKline) — were approved by the US FDA for the treatment of erectile dysfunction. Can they challenge the dominance of the first PDE5 inhibitor, sildenafil citrate (Viagra; Pfizer), which rapidly became a blockbuster following its market entry in the late 1990s?
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
